Efficacy of cytotoxic T lymphocytes against virus-induced tumors.
Cytotoxic T lymphocytes (CTLs) against virus-induced tumors are highly effective mediators of tumor-specific immunity in vivo. CTLs bearing the surface molecule CD8 recognize small (approximately 10-amino-acid) viral peptides that are presented in association with major histocompatibility (MHC) class I molecules at the surface of tumor cells. In the case of mouse tumors induced by the early region (E1) of human adeno-virus type 5 (Ad5), cloned CD8+ CTLs directed against a peptide derived from the viral nuclear oncogene product E1A can rapidly eradicate large established tumors, provided that interleukin-2 (IL-2) is given simultaneously. Similar findings have been reported for other virus-induced tumors. Conceivably, adoptive therapy with CD8+ CTLs could be extended to tumors that originate in other ways, including those arising through activation or mutation of cellular oncogenes.
Melief
C J
CJ
Division of Immunology, The Netherlands Cancer Institute, Amsterdam.
Kast
W M
WM
D017456:Adenovirus Early Proteins; D006801:Humans; D007116:Immunization, Passive; D007376:Interleukin-2 / Q000494:pharmacology; D009856:Oncogene Proteins, Viral / Q000276:immunology; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*; D014412:Tumor Virus Infections / Q000276:immunology / Q000628:therapy*
D017456:Adenovirus Early Proteins; D007376:Interleukin-2; D009856:Oncogene Proteins, Viral